Nasdaq · Healthcare
CorMedix Inc. (CRMD)
As-reported financials and recent SEC filings for CorMedix Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$311.7M
Net income
$163.1M
Net margin
52.3%
Diluted EPS
$2.04
ROE
40.2%
P/E (TTM)
3.6×
Market cap
$615.8M
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $311.7M | $43.5M | — | $65,408 | $190,936 |
| Gross profit | — | — | — | — | $41,998 |
| Operating income | $150.1M | $-22.4M | $-49.0M | $-30.6M | $-29.4M |
| Net income | $163.1M | $-17.9M | $-46.3M | $-29.7M | $-28.2M |
| Diluted EPS | $2.04 | $-0.30 | $-787.15 | $-640.10 | $-648.75 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
S-8 POS2026-06-25
View on EDGAR →8-K2026-06-24
View on EDGAR →SCHEDULE 13G/A2026-06-12
View on EDGAR →SCHEDULE 13G/A2026-06-12
View on EDGAR →8-K2026-06-08
View on EDGAR →SCHEDULE 13G/A2026-05-15
View on EDGAR →10-Q2026-05-14
View on EDGAR →8-K2026-05-14
View on EDGAR →Go deeper on CRMD
Search CorMedix Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.